ANI Pharmaceuticals (ANIP) Projected to Post Quarterly Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect ANI Pharmaceuticals to post earnings of $1.37 per share and revenue of $179.75 million for the quarter.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded up $0.55 on Wednesday, reaching $70.82. 287,058 shares of the company's stock traded hands, compared to its average volume of 287,631. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $73.72. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -128.76 and a beta of 0.56. The stock has a 50 day moving average price of $66.45 and a 200-day moving average price of $60.55.

Analysts Set New Price Targets

A number of brokerages have recently commented on ANIP. HC Wainwright restated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Guggenheim reaffirmed a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research report on Monday, April 21st. Finally, Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a "buy" rating and a $80.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $80.13.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares of the company's stock, valued at $5,526,799.20. This trade represents a 0.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock valued at $197,792. 12.70% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.